title: Strontium ranelate (Fujisawa/Servier).
abstract: Strontium ranelate (PROTELOS), a divalent strontium salt, has been developed and launched by Servier for the treatment of osteoporosis. Fujisawa Pharmaceutical is developing the drug in Japan; in November 2004, phase II Japanese trials were ongoing.
authors.affiliation: Bone and Cartilage Metabolism Research Unit. CHU Centre-Ville, Policliniques L Brull, Quai Godefroid Kurth 45, 4020 Liège, Belgium.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Jupsin
authors.forename: Julien
authors.initials: J
authors.lastname: Collette
authors.forename: Yves
authors.initials: Y
authors.lastname: Henrotin
authors.forename: Olivier
authors.initials: O
authors.lastname: Bruyere
authors.forename: Nathalie
authors.initials: N
authors.lastname: Sarlet
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy; D004345:Drug Industry / Q000191:economics / Q000379:methods; D005260:Female; D006801:Humans; D009942:Organometallic Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000453:epidemiology; D013876:Thiophenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate